LORIS Robustly Predicts Patient Outcomes with Immune Checkpoint Blockade Therapy Using Common Clinical, Pathologic and Genomic Features

0
19
Investigators analyzed a large dataset of 2,881 immune checkpoint blockade (ICB)-treated and 841 non-ICB-treated patients across 18 solid tumor types, encompassing a wide range of clinical, pathologic and genomic features.
[Nature Cancer]
Abstract